1. Unveiling the mechanism of action of nature-inspired anti-cancer compounds using a multi-omics approach
    Nelson C. Soares et al, 2022, Journal of Proteomics CrossRef
  2. Crosstalk between Ca2+ Signaling and Cancer Stemness: The Link to Cisplatin Resistance
    Sana Kouba et al, 2022, IJMS CrossRef
  3. Metformin Improves Ovarian Cancer Sensitivity to Paclitaxel and Platinum-Based Drugs: A Review of In Vitro Findings
    Giovanni Tossetta, 2022, IJMS CrossRef
  4. Role of RAS signaling in ovarian cancer
    Lubna Therachiyil et al, 2022, F1000Res CrossRef
  5. Immunogenic cell death-related gene landscape predicts the overall survival and immune infiltration status of ovarian cancer
    Wenwen Zhang et al, 2022, Front. Genet. CrossRef
  6. A trans-Pt(ii) hedgehog pathway inhibitor complex with cytotoxicity towards breast cancer stem cells and triple negative breast cancer cells
    Aisling L. Ryan et al, 2022, Dalton Trans. CrossRef
  7. New progress of glutamine metabolism in the occurrence, development, and treatment of ovarian cancer from mechanism to clinic
    Xiaojing Yang et al, 2022, Front. Oncol. CrossRef
  8. Therapy-Induced Stromal Senescence Promoting Aggressiveness of Prostate and Ovarian Cancer
    Elisa Pardella et al, 2022, Cells CrossRef
  9. Targeting the NRF2/KEAP1 pathway in cervical and endometrial cancers
    Giovanni Tossetta et al, 2023, European Journal of Pharmacology CrossRef
  10. Identification of EMP1 as a critical gene for cisplatin resistance in ovarian cancer by using integrated bioinformatics analysis
    Qingsong Zeng et al, 2023, Cancer Medicine CrossRef
  11. Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance
    Ebrahim H. Maleki et al, 2023, Genes & Diseases CrossRef
  12. Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrug–Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines
    Marie-Christin Barth et al, 2023, IJMS CrossRef
  13. Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
    Shicheng Yang et al, 2023, Front. Oncol. CrossRef
  14. Differential molecular pathway expression according to chemotherapeutic response in ovarian clear cell carcinoma
    Min Yin et al, 2023, BMC Women's Health CrossRef
  15. A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis
    Philipp König et al, 2023, Cancer Chemother Pharmacol CrossRef
  16. Aberrant epigenetic regulation of FZD3 by TET2 is involved in ovarian cancer cell resistance to cisplatin
    Li Zhu et al, 2023, Journal of Chemotherapy CrossRef
  17. Mechanisms of autophagy and endoplasmic reticulum stress in the reversal of platinum resistance of epithelial ovarian cancer cells by naringin
    Jun Zhu et al, 2023, Mol Biol Rep CrossRef
  18. Targeting the stimulator of interferon genes (STING) in breast cancer
    Ma Ying-Rui et al, 2023, Front. Pharmacol. CrossRef
  19. Scutellaria baicalensis Georgi and Their Natural Flavonoid Compounds in the Treatment of Ovarian Cancer: A Review
    Jiaying Cai et al, 2023, Molecules CrossRef
  20. Potentiation of Cisplatin Cytotoxicity in Resistant Ovarian Cancer SKOV3/Cisplatin Cells by Quercetin Pre-Treatment
    Aseel Ali Hasan et al, 2023, IJMS CrossRef
  21. Single-cell RNA sequencing reveals a pro-metastatic subpopulation and the driver transcription factor NFE2L1 in ovarian cancer cells
    Junseong Park et al, 2023, Genes Genom CrossRef
  22. Chemotherapy‐induced release of ADAM17 bearing EV as a potential resistance mechanism in ovarian cancer
    Gerrit Hugendieck et al, 2023, J of Extracellular Vesicle CrossRef
  23. Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers
    Tetiana Korzun et al, 2023, Small CrossRef
  24. Glucose-6-phosphate dehydrogenase: a therapeutic target for ovarian cancer
    Chenxi Wang et al, 2023, Expert Opinion on Therapeutic Targets CrossRef
  25. Enzymatically crosslinked magnetic starch-grafted poly(tannic acid) hydrogel for “smart” cancer treatment: An in vitro chemo/hyperthermia therapy study
    Morteza Eskandani et al, 2023, International Journal of Biological Macromolecules CrossRef
  26. Snail transcription factors as key regulators of chemoresistance, stemness and metastasis of ovarian cancer cells
    Michal Kielbik et al, 2023, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
  27. Nano-curcumin formulations for targeted therapy of colorectal cancer
    Hossein Shahdadi Sardou et al, 2023, Journal of Drug Delivery Science and Technology CrossRef
  28. Auranofin Induces Lethality Driven by Reactive Oxygen Species in High-Grade Serous Ovarian Cancer Cells
    Farah H. Abdalbari et al, 2023, Cancers CrossRef
  29. Meta‐analysis of microarray data to determine gene indicators involved in the cisplatin resistance in ovarian cancer
    Somayeh Hashemi Sheikhshabani et al, 2023, Cancer Reports CrossRef
  30. PINK1-PTEN axis promotes metastasis and chemoresistance in ovarian cancer via non-canonical pathway
    Fang Zheng et al, 2023, J Exp Clin Cancer Res CrossRef
  31. Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
    Sevgi Ayhan et al, 2023, J Ovarian Res CrossRef
  32. CT radiomics prediction of CXCL9 expression and survival in ovarian cancer
    Rui Gu et al, 2023, J Ovarian Res CrossRef
  33. Mitophagy-related long non-coding RNA signature predicts prognosis and drug response in Ovarian Cancer
    Jiao Wang et al, 2023, J Ovarian Res CrossRef
  34. CD39+MDSC Facilitates Cisplatin Resistance of Ovarian Cancer Cells by Affecting Adenosine Synthesis
    Jiong Ma et al, 2023, CPD CrossRef
  35. The microbiome and ovarian cancer: insights, implications, and therapeutic opportunities
    Yogita Mehra et al, 2023, J Cancer Metastasis Treat CrossRef
  36. null
    Andrea Cuschieri et al, 2023 CrossRef
  37. Beyond Sterilization: A Comprehensive Review on the Safety and Efficacy of Opportunistic Salpingectomy as a Preventative Strategy for Ovarian Cancer
    Tahereh Zadabedini Masouleh et al, 2023, Current Oncology CrossRef
  38. The impact of PARP inhibitors in the whole scenario of Ovarian Cancer management: a Systematic Review and Network Meta-Analysis
    Nicoletta Staropoli et al, 2023, Critical Reviews in Oncology/Hematology CrossRef
  39. Deep learning enhanced the diagnostic merit of serum glycome for multiple cancers
    Haobo Zhang et al, 2024, iScience CrossRef
  40. A benzimidazolium salt induces apoptosis and arrests cells at sub-G1 phase in epithelial ovarian cancer cells
    Sakine Akar et al, 2024, Mol Biol Rep CrossRef
  41. Trps1 predicts poor prognosis in advanced high grade serous ovarian carcinoma
    Xiaojiang Wang et al, 2024, Intl Journal of Cancer CrossRef
  42. Methylene Blue Metabolic Therapy Restrains In Vivo Ovarian Tumor Growth
    Jorgelindo da Veiga Moreira et al, 2024, Cancers CrossRef
  43. Combined radiomics-clinical model to predict platinum-sensitivity in advanced high-grade serous ovarian carcinoma using multimodal MRI
    Inye Na et al, 2024, Front. Oncol. CrossRef
  44. ITGB2 fosters the cancerous characteristics of ovarian cancer cells through its role in mitochondrial glycolysis transformation
    Li Guo-Wei et al, 2024, Aging CrossRef
  45. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target
    Wei Li et al, 2024, BMC Genomics CrossRef
  46. null
    Katie E. Allen et al, 2023 CrossRef
  47. HMGB1 enhances the migratory and invasive abilities of A2780/DDP cells by facilitating epithelial to mesenchymal transition via GSK‑3β
    Jinhua Wang et al, 2024, Exp Ther Med CrossRef
  48. Hsa_circ_0000585 promotes chemoresistance to cis-platin in epithelial cells of ovarian cancer by modulating autophagy
    Pei Du et al, 2023, Biochemical and Biophysical Research Communications CrossRef
  49. Apurinic/apyrimidinic endodeoxyribonuclease 1 (APE1) promotes stress granule formation via YBX1 phosphorylation in ovarian cancer
    Shuyu Mao et al, 2024, Cell. Mol. Life Sci. CrossRef
  50. Refining molecular subtypes and risk stratification of ovarian cancer through multi‐omics consensus portfolio and machine learning
    Jing Zhang et al, 2024, Environmental Toxicology CrossRef
  51. Enhancing precision medicine: a nomogram for predicting platinum resistance in epithelial ovarian cancer
    Ruyue Li et al, 2024, World J Surg Onc CrossRef
  52. A Stem-like Patient-Derived Ovarian Cancer Model of Platinum Resistance Reveals Dissociation of Stemness and Resistance
    Tise Suzuki et al, 2024, IJMS CrossRef
  53. Photo-responsive doxorubicin delivery: Nanogel systems based on azobenzene and host-guest interactions enhanced by squeezing action
    Samaneh Yousefi Adlsadabad et al, 2024, Polymer CrossRef
  54. Exploring the Antiproliferative and Modulatory Effects of 1-Methoxyisobrassinin on Ovarian Cancer Cells: Insights into Cell Cycle Regulation, Apoptosis, Autophagy, and Its Interactions with NAC
    Martina Zigová et al, 2024, Molecules CrossRef
  55. Therapeutic strategies targeting folate receptor α for ovarian cancer
    Jia Mai et al, 2023, Front. Immunol. CrossRef
  56. TCEB3 initiates ovarian cancer apoptosis by mediating ubiquitination and degradation of MCL‐1
    Ying Cai et al, 2024, The FASEB Journal CrossRef
  57. Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options
    Mariana Nunes et al, 2024, Cells CrossRef
  58. Iron promotes ovarian cancer malignancy and advances platinum resistance by enhancing DNA repair via FTH1/FTL/POLQ/RAD51 axis
    Qingyu Zhang et al, 2024, Cell Death Dis CrossRef
  59. Targeting ferroptosis in ovarian cancer: Novel strategies to overcome chemotherapy resistance
    Celine Kapper et al, 2024, Life Sciences CrossRef
  60. CD276 enhances sunitinib resistance in clear cell renal cell carcinoma by promoting DNA damage repair and activation of FAK-MAPK signaling pathway
    Zhi-yu Zhang et al, 2024, BMC Cancer CrossRef
  61. The role of chaperone-mediated autophagy in drug resistance
    Ana Beatriz da Silva Teixeira et al, 2024, Genet. Mol. Biol. CrossRef
  62. Dual‑regulated oncolytic adenovirus carrying ERCC1‑siRNA gene possesses potent antitumor effect on ovarian cancer cells
    Ting Zhao et al, 2024, Mol Med Rep CrossRef
  63. Effects of metformin on cancers in experimental and clinical studies: Focusing on autophagy and AMPK/mTOR signaling pathways
    Mohammad Yasin Zamanian et al, 2024, Cell Biochemistry & Function CrossRef
  64. Lactate drives the ESM1–SCD1 axis to inhibit the antitumor CD8+ T-cell response by activating the Wnt/β-catenin pathway in ovarian cancer cells and inducing cisplatin resistance
    Zhiwen Fan et al, 2024, International Immunopharmacology CrossRef